Skip to content
Clinical Trials – home

Universitaetsklinikum Krems

Research site

Austria Mitterweg 10, 3500 Krems An Der Donau, Austria

  • 16 trials recruiting
  • Non-small cell lung cancer · Plasma cell myeloma · Idiopathic pulmonary fibrosis
  • Adults and children

About Specializations

Universitaetsklinikum Krems in Krems An Der Donau, Austria specialises in clinical trials of conditions such as Non-small cell lung cancer, Plasma cell myeloma, Idiopathic pulmonary fibrosis, Bladder cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Hematology and Blood Cancers at Universitaetsklinikum Krems

Research in Hemic and Lymphatic Diseases focuses on major blood cancers, especially multiple myeloma and follicular lymphoma. These trials are mainly designed to improve treatment effectiveness, deepen responses, and measure minimal residual disease so doctors can better understand how well therapy is working.

  • New approaches for newly diagnosed and relapsed/refractory multiple myeloma
  • Studies of maintenance therapy and deeper response assessment, including MRD negativity
  • Trials in follicular lymphoma comparing targeted treatment strategies

The site is active in testing therapies that aim to extend remission and refine long-term disease control in hematologic malignancies.

Solid Tumor Oncology

Within Neoplasms, the site is studying several advanced cancers, including non-small cell lung cancer, small cell lung cancer, bladder cancer, prostate cancer, and breast cancer. The main goal is to evaluate new cancer therapies, compare them with current standards, and identify treatments that may improve survival and tumor response.

  • Trials in advanced lung cancer, including biomarker-driven and first-line treatment strategies
  • Studies for bladder cancer and muscle-invasive bladder cancer focused on treatment effectiveness
  • Research in metastatic prostate cancer and ER+/HER2- advanced breast cancer

This oncology program at Universitaetsklinikum Krems emphasizes targeted therapy, immunotherapy, and combination treatment approaches for difficult-to-treat cancers.

Respiratory and Lung Disease Research

Trials in Respiratory Tract Diseases are centered on idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and other interstitial lung diseases. These studies aim to slow lung function decline, improve symptoms such as cough, and assess whether new therapies can better control chronic fibrotic lung disease.

  • Studies in idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease
  • Research on systemic autoimmune rheumatic disease-associated interstitial lung disease
  • Trials evaluating symptom relief, including treatment for persistent cough

This field reflects a strong interest in improving both lung function and day-to-day quality of life for people with chronic pulmonary fibrosis.

Immune-Mediated and Inflammatory Diseases

The site also conducts research in Immune System Diseases, including ulcerative colitis and Crohn's disease. These trials are designed to test new therapies that may reduce inflammation, improve disease control, and support better long-term management of chronic immune-related conditions.

  • Studies of ulcerative colitis aimed at improving induction and maintenance treatment
  • Trials in Crohn's disease assessing control of active disease
  • Research focused on safer and more effective immune-targeted therapies

At Universitaetsklinikum Krems, this area complements the oncology portfolio by advancing therapies that modulate immune activity in a clinically meaningful way.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Mitterweg 103500 Krems An Der DonauAustria
Recruiting now
16 trials
Conditions studied
22

More sites in Krems An Der DonauAustria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

39 clinical trials

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.